From Innovation to Regeneration

Nohla is leading the development of ex vivo expanded, universal, off-the-shelf allogeneic cellular therapies for patients with hematologic malignances and other critical diseases.

Innovation

(Our Science)

Regeneration

(Our Products)

2
Ongoing Phase 2 Trials
115
Patients Treated w/ NLA101
15
Years of Research
35
WW Cord Blood Transplants

Ongoing Trials

NLA101 is currently under evaluation in two large randomized, multi-center Phase 2 studies. The first is an ongoing Phase 2b study in the US for patients with acute leukemia, MDS or CML undergoing a myeloablative CBT. The second Phase 2 trial is a global study intended to enroll 220 patients with AML who are at risk for neutropenia following high dose chemotherapy.

Patient Stories

As a late stage clinical therapeutics company, Nohla Therapeutics’ universal donor product has been used to treat over 100 patients, bringing hope to patients who previously had limited options.

Press Releases

Events & Presentations

Nohla is a leading developer of ex vivo expanded, universal, off-the-shelf allogeneic cellular therapies for patients with hematologic malignances and other critical diseases.